

PATENT  
Serial No. 08/372,676  
Docket No. 304142800300  
Docket No. 434-047

the application and the finality of the Office Action in view of the following Amendments and Remarks is respectfully requested.

AMENDMENTS

Please amend the claims as follows:

Please cancel all currently pending claims in the application without prejudice (Claims 1 and 4-26).

Please add the following new claims:

1 ~~27~~. (New) An antibody having all the identifying characteristics of monoclonal antibody 1A7 produced by the hybridoma deposited under ATCC Accession No. HB-11786.

2 ~~28~~. (New) Hybridoma designated 1A7 having ATCC Accession No. HB-11786, or progeny thereof producing a monoclonal antibody having all the identifying characteristics of the antibody produced by said hybridoma 1A7.

3 ~~29~~. (New) Monoclonal antibody produced by the hybridoma or the progeny thereof according to claim ~~28~~. 2

4 ~~30~~. (New) Monoclonal antibody purified from the hybridoma or the progeny thereof according to claim ~~28~~. 2

5 ~~31~~. (New) A purified antibody having all the identifying characteristics of an antibody produced by the hybridoma according to claim ~~28~~. 2

25

PATENT  
Serial No. 08/372,676  
Docket No. 304142800300  
Docket No. 434-047

6 ~~32~~. (New) An antibody according to claim ~~27~~<sup>1</sup> wherein said antibody further comprises a detectable label.

19 7 ~~33~~. (New) An antibody according to claim ~~32~~<sup>6</sup>, wherein said detectable label is selected from the group consisting of radiolabels, fluorescent labels and chemiluminescent labels.

8 ~~34~~. (New) A diagnostic test kit for detecting an anti-GD2 antibody in a biological sample, comprising an antibody according to claim ~~27~~<sup>1</sup> in a suitable container.

9 ~~35~~. (New) The diagnostic kit of claim ~~34~~<sup>8</sup>, wherein the antibody is capable of binding anti-GD2.

10 ~~36~~. (New) The diagnostic kit of claim ~~34~~<sup>8</sup>, wherein the antibody is labeled with a detectable label.

11 ~~37~~. (New) The diagnostic kit of claim ~~34~~<sup>8</sup>, wherein the detectable label is selected from the group consisting of radiolabels, fluorescent labels, and chemiluminescent labels.

12 ~~38~~. (New) The diagnostic kit of claim ~~34~~<sup>8</sup>, also comprising an anti-immunoglobulin reagent labeled with a detectable label.

13 ~~39~~. (New) The diagnostic kit of claim ~~34~~<sup>8</sup>, wherein the biological sample is obtained from an individual suspected of having a GD2 antigen associated cancer.